BioSpace News Archive

OPKO Health, Inc. announced that management will be participating in the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 at the Westin St. Francis in San Francisco.

Immunovant, Inc. announced the closing of its business combination with Immunovant Sciences Ltd., a clinical stage biopharmaceutical company developing IMVT-1401, a fully human monoclonal antibody that selectively binds to and inhibits the neonatal Fc receptor and is designed to be delivered by subcutaneous injection.

LignaMed, LLC announced published preclinical data demonstrated that lead candidate LGM2605 is highly efficacious in producing a protective effect on Airway Hyperreactivity in a model of Th2-low asthma, a subtype of glucocorticoid resistant asthma.

CytomX Therapeutics, Inc. provided an update on its lead programs and 2020 clinical portfolio outlook.

Selecta Biosciences, Inc. announced that it has entered into definitive agreements to sell securities in a private placement with a group of institutional investors and certain members of the Company’s Board of Directors.

An editorial published in NEJM by Jane E. Salmon, MD, suggests regulators should require that only one of two outcomes should be met

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, appointed Elaine Caughey to the role of chief business officer.

Scientists will have new view into natural cell activity, accelerating drug development

Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease

AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease